rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Matthew Kiernan

Director

Company insider

Files Form 4 as: Director, Clene.

Every Form 4 they filed

In numbers

Trades disclosed
19
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
1
First trade
28 Nov 2023
Last trade
13 Aug 2026
Last filed
14 Aug 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
CLNN CleneDirector · Biotechnology · last 13 Aug 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
13 Aug 2026filed 14 Aug 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—3,195 at $0.00filing
13 Aug 2026filed 14 Aug 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—3,195 at $0.00filing
21 May 2026filed 22 May 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—1,500 at $0.00filing
21 May 2026filed 22 May 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—1,876 at $0.00filing
21 May 2026filed 22 May 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—1,500 at $0.00filing
21 May 2026filed 22 May 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—1,876 at $0.00filing
19 Feb 2026filed 20 Feb 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—2,755 at $0.00filing
19 Feb 2026filed 20 Feb 2026CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—2,755 at $0.00filing
13 Nov 2025filed 14 Nov 2025CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—1,893 at $0.00filing
14 Aug 2025filed 15 Aug 2025CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—3,720 at $0.00filing
22 May 2025filed 23 May 2025CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—1,500 at $0.00filing
22 May 2025filed 23 May 2025CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—5,236 at $0.00filing
27 Feb 2025filed 28 Feb 2025CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—2,886 at $0.00filing
6 Dec 2024filed 9 Dec 2024CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—2,853 at $0.00filing
2 Oct 2024filed 3 Oct 2024CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—2,559 at $0.00filing
7 Jun 2024filed 10 Jun 2024CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—33,704 at $0.00filing
29 May 2024filed 31 May 2024CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
11 Mar 2024filed 12 Mar 2024CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—29,481 at $0.00filing
28 Nov 2023filed 29 Nov 2023CLNN Cleneoption or derivative · BiotechnologySEC FORM 4 Code A—28,730 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Robert Dee EtheringtonPresident & CEO · President & CEO at Clene, filing Form 4 there in the last year
Morgan R. BrownChief Financial Officer · Chief Financial Officer at Clene, filing Form 4 there in the last year
Mark MortensonChief Science Officer · Chief Science Officer at Clene, filing Form 4 there in the last year
David J. MatlinDirector · Director at Clene, filing Form 4 there in the last year
Alison MoscaDirector and 10% owner · Director and 10% owner at Clene, filing Form 4 there in the last year